Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLC

Publication
Video
Special ReportsNSCLC (Issue 11)
Volume 4
Issue 2

Howard L. &ldquo;Jack&rdquo; West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent&nbsp;<em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).

Howard L. &ldquo;Jack&rdquo; West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrentEGFR-mutant non-small cell lung cancer (NSCLC).

While not yet available for use in the United States, the European Medicines Agency approved the combination in June 2016 and West says he regularly uses it.

Related Videos
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
The Oncology Brothers with Joshua K. Sabari, MD, presenting slides
Related Content